The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Ondine is a gamechanger. I invested in Immupharma in Jan/Feb and posted multiple reasons to buy at 1.3p. It has doubled in under a month. Ondine is similarly undervalued It's technology is cutting edge and is now snowballing after years of proof of concept and first-mover adoption.
Reducing antibiotic use is the single biggest driver in global Healthcare as we are unprepared for the next (inevitable) pandemic. Steriwave goes a long way to helping resolve Hospital acquired infections and it's multiple potential applications are being addressed. I can see many major companies being interested in picking up this tiddler before it flies above the radar.
Like yourself, having done lengthy background research I expect this to be a highly rewarding share. The timeframe I set myself is medium to long term rising progressive from around this level. There is always the underlying possibility that newsflow or an opportunistic bid could cause this to rise disproportionately.
Apart from the fact that the sale of a block of 11% INC shares could certainly be sold at this time OFF market, the sale is neither necessary nor desirable at present. Newsflow on several fronts is imminent and this is the perfect time imo to grab the baton. DTR and make your own decisions here don't rely on posters like me or Flash or anyone else. All the information you need to make an informed decision is there and, like me, you can contact Immupharma yourself to aid your thought process.
It's all conjecture. The facts are out there with Lupuzor lined up for a funded Ph3 trial and 4 other candidates for potential upfront Royalty deals. We have the never ending concentration however on funding. Cash is tight until newsflow, as promised, is forthcoming but prudent management has many options. Immupharma has over £1 of Incanthera shares which it could capitalise tomorrow IF required. The fact that it has not happened means funds are ok as the CEO has previously assured. Personally, I'd prefer them to keep the INC shares for future dividends but needs must. I just disagree fundamentally with the debate revolving around a non existent issue when so many short term triggers are already set. Patience, positive news will flow soon.
Lupuzor is awaiting its Ph3 trials protocols and then patient recruitment which always focuses investor attention from a wider audience (Avion is funding at no cost to Immupharma). An RNS to that effect is going to be the only short term trigger on Lupuzor. There is also possible newsflow from any of the other four candidate drugs regarding development. The ONLY thing stopping this share taking off is continued concern over funding. The CEO said there was a cash runway to end 2024 but that is being questioned as is evident on this board. Any confirmation of funds, Royalty financing, licensing deal or ironically a significant increase in share price would immediately erase those concerns and it would take off here. The nature of the Lanstead deal means that any share increase over 2p has a chain reaction increase in finances but a decrease progressively reduces funds. You pays your money and takes your choice basically. DYOR. However, were one or all of the BoD to buy shares........
2 directly opposed views then.....how unusual. The constant, negative can't do brigade are that ones thar shackle British entrepreneurs and first movers. That's why so many companies are choosing to list in the US the land of can do optimism. The reversal here will take all by surprise.
I am at a loss to see how low the MCap has become given the potential upside and intrinsic value of IP. Why Avion and parent Alora are not just buying Immupharma outright totally confounds me. It must surely be being considered.
That would provide a cash runway well into 2025 by which time any one or all of the 5 candidate products should have filled the coffers and more putting the MCap towards its £50m value as Lupuzor Ph3 proceeds.
Best idea would be for Immupharma to divest Incanthera shares (yes I know it would be a paper loss) but £1.1m hard cash NOW would shut up all the diatribe on cahflow and allow the company to concentrate on its pharmaceutical innovative products.
Avion has confirmed funding of the Ph3 Lupuzor trial and is committed to seeing it through. By now taking over Immupharma it would secure total world rights for itself plus P140 for CIDP Chronic Inflammatory Demyelinating Polyneuropathy and Anti-infectives BioAMB for systemic fungal infections and BioCIN for systemic bacterial infections. It also gets collaboration with Orano in radiopharmaceuticals PLUS over £1m of rising Incanthera shares and 7m warrants in INC exercisable at 9.5p. If that's not a compelling target I'm amazed.
Whilst we await news on the Ph3 clinical trial for Lupuzor the team should be focused on extracting value via partnerships on P140 for CIDP Chronic Inflammatory Demyelinating Polyneuropathy
Anti-infectives BioAMB and for systemic fungal infections
BioCIN.
Also if Orano decide to partner or extend their 12 month collaboration with Immupharma (3/23 to 3/24), that could be interesting.
Yes, finances are quite tight but there are multiple options for a prudent team such as bridge finance , INC warrant swaps (7m) or INC share sale (10m held).
One of the key points of optimism for me was the interim statement:
The drive to conclude further commercial and partnering deals will be accelerated over this next period and which is now bolstered by the recently announced new Board appointments.
We await news.........
The first Ph3 announcement will be registration with clinicaltrials regarding pre-rrgistration of patients. That should focus interest. The protocol will give details of dosage escalation, end-point and (more importantly) the 2 interim assessments.
The other produ ts in Immupharma's p/f may well provide first news.